Fujifilm picks Holly Springs for new facility

By The Science Advisory Board staff writers

March 18, 2021 -- Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, viral vaccines, and gene therapies, announced it will build what will be the country's largest cell culture production facility in Holly Springs, NC.

The $2 billion investment will create 725 highly skilled jobs in the Holly Springs area by the end of 2028, according to the company.

The new facility will offer large-scale cell culture manufacturing of bulk drug substance production with eight 20,000-L bioreactors with the potential to expand and add a further 24 20,000-L bioreactors based on market demand. In addition, the facility will also provide commercial scale, automated fill-finish and assembly, packaging, and labeling services. The facility is expected to be operational by spring 2025.

Holly Springs was selected for its strong pool of technical talent, local resources, and partners with the right competencies, clean energy resources, and sustainability for future growth, the company stated.

Fujifilm Diosynth celebrates expansion in Denmark
Contract development and manufacturing organization Fujifilm Diosynth Biotechnologies held a ceremony on March 3 to celebrate the large-scale expansion...
Fujifilm secures funding, signs lease for new research/manufacturing center
Fujifilm Diosynth Biotechnologies has announced $76 million in financing for the Center for Advanced Biological Innovation and Manufacturing and...
Fujifilm invests $2B on cell culture manufacturing
Fujifilm plans to invest more than $2 billion to build a large-scale cell culture manufacturing site for biopharmaceuticals in the U.S.
Fujifilm Diosynth to establish viral vector manufacturing in Boston
Contract development and manufacturing organization Fujifilm Diosynth Biotechnologies will establish a new process development and manufacturing facility...
Allterum, FujiFilm begin development, scale-up of monoclonal antibodies for leukemia
Allterum Therapeutics has received a $2.9 million product development grant from the Cancer Research and Prevention Institute of Texas to support...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter